Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16512729 | 0.82 | GRM4 (0.45) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL16371764 | 0.78 | GAA (0.48) | LMNAGAAKCNK3KCNK9P2RX7 | |
| SCHEMBL27486980 | 0.77 | MEN1 (0.63) | LMNAGAACTNNB1WNT3ATP53 | |
| SCHEMBL30417052 | 0.77 | MEN1 (0.63) | LMNAGAACTNNB1WNT3ATP53 | |
| SCHEMBL16485993 | 0.76 | RECQL (0.43) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL16372308 | 0.76 | LMNA (0.59) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL16371758 | 0.76 | LMNA (0.55) | LMNAGAAKCNK3KCNK9PTGS1 | |
| Hydrochloric Acid SCHEMBL30416887 | 0.76 | MEN1 (0.61) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL16392354 | 0.76 | PTPRC (0.48) | LMNAGAAKCNK3KCNK9P2RX7 | |
| SCHEMBL16372385 | 0.76 | LMNA (0.46) | LMNAGAAKCNK3KCNK9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| EP-3033330-B1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176806-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| EP-3033330-A2 | NOVEL COMPOUNDS | Syngenta Participations AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022265-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022265-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176806-A1 | NOVEL COMPOUNDS | SGMS1, DDT, CYP1B1 | LMNA 2782/4885GAA 626/4885KCNK3 2964/4885 |
| US-10207985-B2 | Compounds | CYP1B1, DDT, CYP1A1 | LMNA 1800/4885GAA 332/4885KCNK3 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.